ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis by Campbell, Craig I et al.
RESEARCH Open Access
ErbB2 enhances mammary tumorigenesis,
oncogene-independent recurrence and
metastasis in a model of IGF-IR-mediated
mammary tumorigenesis
Craig I Campbell, James J Petrik, Roger A Moorehead
*
Abstract
Background: The type I insulin-like growth factor receptor (IGF-IR) and ErbB2 (Her-2) are receptor tyrosine kinases
implicated in human breast cancer. Both proteins are currently the subject of targeted therapeutics that are used
in the treatment of breast cancer or which are in clinical trials. The focus of this study was to utilize our inducible
model of IGF-IR overexpression to explore the interaction of these two potent oncogenes.
Results: ErbB2 was overexpressed in our RM11A cell line, a murine tumor cell line that overexpresses human IGF-IR
in an inducible manner. ErbB2 conferred an accelerated tumor onset and increased tumor incidence after injection
of RM11A cells into the mammary glands of syngeneic wild type mice. This was associated with increased
proliferation immediately after tumor cell colonization of the mammary gland; however, this effect was lost after
tumor establishment. ErbB2 overexpression also impaired the regression of established RM11A tumors following
IGF-IR downregulation and enhanced their metastatic potential.
Conclusion: This study has revealed that even in the presence of vast IGF-IR overexpression, a modest increase in
ErbB2 can augment tumor establishment in vivo, mediate resistance to IGF-IR downregulation and facilitate
metastasis. This supports the growing evidence suggesting a possible advantage of using IGF-IR and ErbB2-directed
therapies concurrently in the treatment of breast cancer.
Background
Receptor tyrosine kinases (RTKs) are transmembrane
proteins with intracellular kinase domains that undergo
phosphorylation in response to ligand binding. This
group of proteins has a well established role in breast
cancer, and thus many RTKs are currently the focus of
directed therapeutics with a significant number of these
therapies in clinical trials. Two such proteins with vali-
dated roles in breast cancer are ErbB2 (also known as
Her2/neu), a member of the epidermal growth factor
receptor family, and the type I insulin-like growth factor
receptor (IGF-IR). A large amount of evidence implicat-
ing both in clinical breast cancer is emerging. In addi-
tion, both receptors have been validated as oncogenes
through the generation and characterization of trans-
genic mouse models (reviewed in [1] and [2]).
The IGF-IR undergoes autophosphorylation on con-
served intracellular tyrosine residues after binding its
ligands IGF-I and IGF-II which subsequently triggers sig-
nal cascades involved in many processes including prolif-
eration and evasion of apoptosis [3]. Common activated
downstream tyrosine kinase cascades include the phos-
phatidyl inositol-3 kinase (PI-3K)/Akt and mitogen acti-
vated protein kinase (MAPK)/Erk1/2 pathways [4]. It is
also widely accepted that the IGF-IR has the capacity to
transform normal cells and its expression is required for
transformation by other known oncogenes [5-8]. Studies
have shown IGF-IR levels are highly expressed in 39-93%
of human breast cancers [9]and in breast tumors expres-
sing high levels of IGF-IR the receptor is expressed
10-14-fold higher on average compared to normal breast
tissue [10,11]. In addition, phosphorylation of IGF-IR was
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which translated to a 40-fold increase in active IGF-IR in
some cases [11]. Regulation of IGF-IR expression in
breast cancer appears quite complex as it has been asso-
ciated with both a poor [12] and favorable prognosis [13]
and may change depending on the stage of the tumor
[14]. In mouse xenografts, syngeneic, and chemically
induced models of mammary carcinogenesis, inhibition
of the IGF-IR through a variety of means has yielded suc-
cess in limiting tumor growth and proliferation [15-19].
In addition, the transforming potential of this protein has
been confirmed with two transgenic mouse models, one
using the native IGF-IR and the other employing a con-
stitutively active form of the receptor [20,21]. In light of
the mounting evidence suggesting a prominent role of
the IGF-IR in breast cancer, numerous targeted therapies
are currently in clinical trials [22,23].
Unlike the IGF-IR and other RTKs, ErbB2 has no
known specific ligand [24]. However, it preferentially
forms heterodimers with other members of the EGF
receptor family, EGFR (ErbB1), ErbB3 and ErbB4 [25].
In addition, ErbB2 heterodimers were determined to
enhance the mitogenic signal of ErbB1 and ErbB3 [26].
Gene amplification with subsequent overexpression of
ErbB2 has also been shown to contribute to the forma-
tion of activated homodimers [27]. Downstream signal-
ing cascades triggered by ErbB2 homo/heterodimers are
very similar to those activated by IGF-IR. ErbB2 is over-
expressed in 25-30% of human breast cancer cases and
is correlated with poor prognosis and shorter disease
free survival [28]. It has been established that human
and mouse ErbB2 variants are capable of transforming
normal murine mammary epithelial cells and NIH/3T3
fibroblasts [29,30]. As stated previously, a number of
transgenic models have validated this observation; ani-
mals overexpressing wild type neu formed tumors with
an average latency of 7 months while with an activated
form of ErbB2, latency was decreased to 3 months [2].
Because of the clinical implications of ErbB2 overexpres-
sion and its transforming potential, a number of direc-
ted therapies have been developed for the treatment of
breast cancer which target ErbB2 alone or in combina-
tion with other RTKs; one of which, trastuzumab (Her-
ceptin) is currently used to treat Her2
+ breast cancer
(reviewed in [31]).
There is a growing body of evidence suggesting an
interaction between the IGF-IR and ErbB2 in clinical
breast cancer. Different studies have shown a physical
interaction between the two receptors through immuno-
precipitation [32-34] and immunofluorescence co-locali-
zation staining [34]. It has also been determined that
knocking down expression of IGF-IR in human breast
cancer cell lines can attenuate ErbB2 phosphorylation;
however, the reciprocal was not observed [34]. In
addition, signaling though the IGF-IR has been shown
to mitigate the growth inhibitory effects of trastuzumab
on human breast cancer cells overexpressing ErbB2 [35];
in fact, it is becoming widely accepted that signaling
through IGF-IR can contribute to resistance to ErbB2-
directed therapies (reviewed in [36]), and it has been
noted that a correlation between IGF-IR expression and
trastuzumab resistance exists in clinical breast cancer
cases [37]. The existence of IGF-IR/ErbB2 heterodimers
has also been established and this association was
shown to contribute to Herceptin resistance in human
breast cancer cell lines; this interaction could be dis-
rupted by treating with monoclonal antibody based ther-
apy to IGF-IR [38]. Based on these findings, a number
of groups have investigated different combinations of
inhibitors of IGF-IR and ErbB2 signaling. Nordihydro-
guaiaretic acid (NDGA), a dual inhibitor of IGF-IR and
ErbB2, was shown to promote cell death in trastuzumab
resistant human breast cancer cell lines [39]. Also, a
synergistic growth inhibitory relationship between tras-
tuzumab and inhibitors of IGF signaling including small
molecule inhibitors of IGF-IR, IGFBP-3 and a dominant
negative IGF-IR has been established in ErbB2 overex-
pressing human breast cancer cell lines [40-42]. An
IGF-IR inhibitor was even found to enhance ErbB2-
mediated apoptosis in a human breast cancer cell line
with very little IGF-IR expression; evidence of this inhi-
bitor augmenting the suppression of ErbB2 phosphoryla-
tion was also discovered [32].
To examine the role of the IGF-IR in breast cancer,
our lab has previously created a doxycycline-inducible
transgenic mouse model (MTB-IGFIR). IGF-IR-induced
transgenic animals develop multiple tumors with 100%
penetrance and an average latency of approximately 50
d [21], with metastasis occurring in approximately 40%
of mice (unpublished observations). From one such pri-
mary tumor, the RM11A cell line was established and
was shown to maintain doxycycline-inducible overex-
pression of the IGF-IR [43]. Enhanced phosphorylation
of downstream signaling molecules Akt and Erk1/2 was
observed upon transgene activation in both tumor tissue
and RM11A cells [21,43]. In vivo, these cells were
shown to form tumors upon injection into the mam-
mary gland of syngeneic, wild type, FVB mice. Because
of its inducible nature, our model can be used to mimic
the effects of IGF-IR-directed therapies through the
deactivation of the transgene, and therefore provides a
unique opportunity to study the potential function of
other known oncogenes during IGF-IR-mediated mam-
mary tumorigenesis. As a number of IGF-IR inhibitory
compounds are currently in clinical trials [23,44], this
model can be used to predict how the inhibition of
other proteins/pathways could be utilized to augment
IGF-IR-directed therapeutics.
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alleviate the requirements of IGF and EGF for prolifera-
tion in a series of human normal and breast cancer cell
lines [45]. However, most studies have focused on IGF
signaling as a mechanism through which clinical cancers
gain resistance to ErbB2-directed therapies. It remains
unclear whether the reciprocal is also true; signaling
through ErbB2 can potentially promote resistance to
IGF-IR-targeted treatments. Also, with the prevalence of
both oncogenes overexpressed in human breast cancer,
it is important to investigate their interaction in mam-
mary tumorigenesis to determine whether it would be
useful to combine therapeutics directed at both ErbB2
and IGF-IR. Thus, our objective was to determine if
ErbB2 overexpression can augment tumorigenesis and
compensate for IGF-IR downregulation in RM11A cells,
a model of IGF-IR-mediated mammary tumorigenesis.
We accomplished this through overexpression of ErbB2
in the RM11A mammary cell line. We then examined
how ErbB2 contributed to cell survival/growth in vitro
and in vivo, cell signaling, primary tumorigenesis, recur-
rence in the absence of IGF-IR transgene expression
and metastasis. In this study, it was determined that a
modest increase in ErbB2 expression could accelerate
primary tumor growth by enhancing proliferation imme-
diately after cell colonization of the mammary gland.
Overexpression of ErbB2 also impaired regression of
tumors in the absence of IGF-IR transgene expression
and facilitated metastasis.
Methods
ErbB2 overexpression construct
A wild type rat ErbB2 (neu) expression construct
(described in [46]) was a generous gift from William
Muller, McGill University, Montreal, QC. Briefly, this
expression construct contained ErbB2 cDNA under the
control of the Moloney murine leukemia virus promoter
which was cloned into the EcoRI and HindIII sites of
pEGFP-N1 (Clontech, Mountain View, CA). This ErbB2
expression plasmid was referred to as pEN1-ErbB2,
while the empty vector was referred to as pEN1. Plasmid
DNA was purified using a Qiagen mini-prep kit (Qiagen,
Mississauga, ON, Canada) in accordance with the manu-
facturer’s instructions.
Western Blotting
Western blotting was performed as previously described
[43]. Primary antibodies used were anti-neu (C-18)
(Santa Cruz Biotechnologies, Santa Cruz, CA) and anti-
C-ErbB2 (pTyr
1222) (AnaSpec, Fremont, CA) both used
at a concentration of 1:250, anti-phospho-Akt, anti-Akt,
anti-phospho-Erk1/2 and anti-Erk1/2 (Cell Signal tech-
n o l o g y ,D a n v e r s ,M A )w e r ea l lu s e da tad i l u t i o no f
1:1,000, as well as anti-IGF-IR (R&D Systems,
Minneapolis, MN) used at a dilution of 1:1,000, and
anti-b-actin used at 1:2,000. The secondary antibody
used was anti-rabbit IgG (Cell Signal technology, Dan-
vers, MA) and was used at a dilution of 1:2,000. Densi-
tometry of the bands was quantified using a FluorChem
9900 imaging system and AlphaEaseFC software version
3.1.2 (Alpha Innotech, San Leandro, CA). Densitometry
values were normalized to those of the loading control,
b-actin, and these normalized numbers were expressed
as values relative to the control.
Cell line and culture conditions
RM11A cells, a cell line previously derived from a tumor
from an MTB-IGF-IR mouse, were maintained in media
as described previously [43]. Cells were continually cul-
tured in media supplemented with 10 μg/mL of doxycy-
cline (Sigma-Aldrich, St. Louis, MO) to maintain high
levels of IGF-IR transgene expression. Transfection was
performed with lipofectamine2000 transfection reagent
(Invitrogen, Burlington, ON, Canada) in accordance
with the manufacturer’s protocol. For ErbB2 overexpres-
sion, RM11A cells were transfected with pEN1-ErbB2
(these cells were called RM11A+Dox/ErbB2); in addi-
tion, cells were transfected with the empty vector to
serve as a control (these cells were called RM11A+Dox).
To select clones with stable integration of the aforemen-
tioned plasmids, cell culture media was supplemented
with G418 (Sigma-Aldrich, St. Louis, MO) at a final
concentration of 750 μg/mL, a concentration previously
validated to kill 100% of untransfected RM11A cells in
3-4 days. After approximately two weeks individual
colonies were isolated and tested for increased ErbB2
expression by Western blotting and subsequently main-
tained with G418. Two control clones and two clones
showing a consistent elevation of ErbB2 were selected
and used for further experiments.
MTT cell survival assays
One thousand RM11A+Dox or RM11A+Dox/ErbB2
cells/well were plated in triplicate in 96-well plates.
Forty-eight hours after plating the cells were incubated
with MTT at a final concentration of 5 mg/mL for 1 h
at 37°C. Cells were then lysed and the absorbance value
at 570 nm was determined. Results represent the aver-
age of seven replicates.
H&E, Immunohistochemistry and immunofluorescence
H&E staining was performed as previously described
[43]. To measure tumor area from H&E stained sec-
tions, slides were scanned using an Aperio Scanscope
(Aperio Technologies, Vista, CA) digital slide scanner,
and measurements were performed using ImageScope
software v. 10.0.36.1805 (Aperio Technologies, Vista,
CA).
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Cells were plated on glass coverslips in 6-well plates at a
d e n s i t yo f3×1 0
4 cells/well. Two days after plating,
cells were fixed and stained as described previously [47].
The primary antibody anti-Ki67 (Abcam, Cambridge,
MA) was used at a dilution of 1:200, while the fluores-
cent conjugated secondary antibody, anti-Rabbit IgG,
was used at a dilution of 1:1,000. Images were captured
using an Olympus BX61 fluorescent microscope (Center
Valley, PA) and MetaMorph version 7.6.0.0 software
(Molecular Devices, Downington, PA) at a magnification
of 200×; positively stained nuclei were counted from 15-
20 fields of view comprising approximately 400-1,000
cells and the proportion of cell nuclei staining positive
for Ki67 was reported. These experiments were repeated
in triplicate.
Immunohistochemistry was performed as previously
described [47]. Anti-Ki67 (Abcam, Cambridge, MA) was
used at a concentration of 1:100. Anti-ErbB2 (Santa
Cruz Biotechnologies, Santa Cruz, CA) was used at a
dilution of 1:100. Appropriate biotinylated secondary
antibodies were used at a concentration of 1:100. For
analysis of Ki67 staining, tumor images were collected at
a magnification of 100× and the proportion of positively
stained nuclei was determined for a minimum of 5 fields
of view.
Animal trials
All mice were housed and utilized following the
guidelines established by the Animal Care Committee
at the University of Guelph and the Canadian Council
on Animal Care. Wild type FVB mice were purchased
from Charles River (Wilmington, MA). At approxi-
mately 4 weeks of age, animals were anesthetized and
both 4
th inguinal mammary glands were injected with
5×1 0
5 RM11A+Dox or RM11A+Dox/ErbB2 cells
resuspended in 10 μLo fP B Su s i n ga2 5μL Hamilton
syringe as described in [43]. Mice were treated with
doxycycline food pellets 2 g/kg (Bio-Serv, Frenchtown,
NY) to maintain IGF-IR overexpression. After tumor
cell injection, mice were either sacrificed after 4 or 14
days or when the tumors reached 15-17 mm in length
(the maximum tumor length allowed by the Canadian
Council for Animal Care is 17 mm). For the latter
condition, mice were monitored for palpable tumors 2
times per week; tumor onset was recorded for both
mammary glands and palpable tumors were measured
(length and width) with digital calipers. Tumor
volume was calculated using the equation: volume =
length × width
2/2. To track tumor growth, two meth-
ods were used. The first method was calculating spe-
cific growth rate (SGR), an established method for
this measurement [48]. In addition, the slope of the
line of log10(tumor volume) versus time(d) was used
to calculate tumor doubling time for validation. For
the tumor regression studies IGF-IR expression was
downregulated when tumors reached 7-11 mm in
length by removing doxycycline from the animals’
diets. Subsequent regression and recurrence in the
absence of IGF-IR transgene expression was moni-
tored as above.
MTB-IGFIR double transgenic mice were used as pre-
viously described [1]. Lungs were collected when pri-
mary tumors reached a maximum of 17 mm in length.
H&E was performed to locate microscopic lung lesions
as described below.
Evaluation of metastasis
Tissue comprising the entire lung from each mouse har-
boring a 15-17 mm length tumor was collected and pro-
cessed as described above. Approximately 25 serial
sections were taken from the middle of each lung. H&E
was performed on sections from the beginning and sec-
ond half of the series. Slides were evaluated for the pre-
sence of metastases using l i g h tm i c r o s c o p yb yt w o
individuals in a blinded manner.
Statistics
Data values are presented as the mean ± SE. Signifi-
cance and p-values were obtained using a Student’st -
test. Differences in metastasis were assessed using a
Fisher’s exact test. Significance between tumor regres-
sion data was calculated using a chi-squared test.
Results
Stable overexpression of ErbB2
The ability of doxycycline to induce elevated IGF-IR
levels in the RM11A cells as well as their in vitro and
in vivo growth characteristics have previously been
reported [43]. To examine how concomitant overex-
pression of IGF-IR and ErbB2 effects mammary tumori-
genesis, ErbB2 was overexpressed in the previously
characterized IGF-IR inducible RM11A cell line [43].
Two independent transfections of pEN1-ErbB2 (an
ErbB2 overexpression construct) and pEN1 (the corre-
sponding control plasmid) with subsequent culture in
media containing G418 resulted in the stable selection
of two pEN1-ErbB2 plasmid integrants and two pEN1
control stable transfectants. RM11A cells overexpressing
IGF-IR but containing the control plasmid were desig-
nated RM11A+Dox while the RM11A cells co-overex-
pressing IGF-IR and ErbB2 were designated RM11A
+Dox/ErbB2. Western blotting was used to confirm ele-
vated expression of ErbB2 in RM11A cells transfected
with the pEN1-ErbB2 plasmid (RM11A+Dox/ErbB2).
Ultimately one RM11A clone from each selection proce-
dure showing the highest and most consistent overex-
pression of ErbB2 (RM11A+Dox/ErbB2) was chosen for
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integrants were generated in parallel to be used as con-
trols (RM11A+Dox). Average overexpression of ErbB2
was approximately 2.5-3-fold compared to RM11A+Dox
cells (Figure 1a, b). Interestingly, two additional bands
were observed in both RM11A+Dox/ErbB2 clones at
approximately 75 and 90 kDa that were not observed in
RM11A+Dox cells (Figure 1a ) .I na d d i t i o n ,W e s t e r n
blots revealed that phospho-ErbB2 levels were consis-
tently increased in RM11A+Dox/ErbB2 cells compared
to RM11A+Dox cells by the same proportion as ErbB2
was upregulated (Figure 1a, b). Western blotting of sig-
naling molecules downstream of IGF-IR and ErbB2
revealed that RM11A+Dox/ErbB2 cells had similar
levels of phosphorylated Akt and Erk1/2 as RM11A
+Dox cells (Figure 1c, d). Therefore, ErbB2 expression
was elevated in RM11A+Dox/ErbB2 cells and ErbB2
was functional as indicated by the increase in phos-
phorylated ErbB2.
Overexpression of ErbB2 did not affect survival/
proliferation in RM11A cells in vitro
We hypothesized that ErbB2 overexpression would
enhance cell survival and proliferation. Survival of
RM11A+Dox and RM11A+Dox/ErbB2 cells was assessed
by MTT assays, while proliferation was quantified using
Ki67 immunofluorescence. ErbB2 overexpression did not
significantly affect proliferation or survival in vitro (data
not shown). Therefore, elevated ErbB2 expression cannot
further enhance survival or proliferation beyond that of
the effect demonstrated by IGF-IR overexpression.
ErbB2 enhances tumorigenesis in vivo
To examine the effects of ErbB2 in a model of IGF-IR
driven mammary tumorigenesis in vivo,R M 1 1 A + D o x
and RM11A+Dox/ErbB2 cells were injected into the
mammary fat pad of wild type syngeneic FVB mice and
tumor onset and growth rates were evaluated. RM11A
+Dox/ErbB2 cells produced palpable mammary tumors
Figure 1 ErbB2 overexpression in RM11A cells did not affect activation of Akt and Erk. ErbB2 and phosphorylated ErbB2 overexpression
were consistently observed by Western blotting in two independent stable clones transfected with the ErbB2 expression construct (RM11A
+Dox/ErbB2) (a). ErbB2 expression was quantified after Western blotting and normalized to the loading control b-actin. Overexpression of both
ErbB2 and pErbB2 was ~2-3 fold higher in both RM11A+Dox/ErbB2 clones compared to RM11A+Dox clones (b). Representative Western blots of
pAkt and pErk (c). Average relative pAkt and pErk levels were determined to be unchanged in RM11A+Dox/ErbB2 cells compared to RM11A
+Dox cells (d).
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significantly shorter than the time required for the
RM11A+Dox cells to form palpable tumors (48 days)
(Table 1). Western blotting c o n f i r m e dt h a te l e v a t e d
ErbB2 expression in the RM11A+Dox/ErbB2 cells was
maintained in vivo; IGF-IR overexpression was also
maintained in tumors derived from both RM11A+Dox
and RM11A+Dox/ErbB2 cells (Figure 2). ErbB2 overex-
pression was also capable of increasing the percentage
of mammary glands that developed tumors (Table 1);
RM11A+Dox/ErbB2 cells were more effective at produ-
cing tumors than RM11A+Dox cells. This data suggests
that ErbB2 can augment IGF-IR mediated mammary
tumorigenesis in vivo by both increasing tumor inci-
dence and decreasing tumor lactency.
To corroborate the tumor onset data, a subset of mice
receiving doxycycline were sacrificed 14 days post tumor
cell injection and the mammary glands were histologi-
cally assessed using hematoxylin and eosin stained sec-
tions. As seen in Figure 3a-f, tumors from RM11A
+Dox/ErbB2 cells (Figure 3d-f) were larger than tumors
from RM11A+Dox cells (Figure 3a-c). The average
tumor area was approximately 4-fold higher in the
RM11A+Dox/ErbB2 tumors compared to RM11A+Dox
tumors at this time point (Figure 3h).
ErbB2 enhances proliferation in RM11A cells in vivo only
after initial mammary gland colonization
To test our hypothesis that ErbB2 overexpression
enhanced initial growth of tumor cells, proliferation was
determined using Ki67 immunohistochemistry at four or
14 days post tumor cell injection. As shown in Figure 4,
proliferation was higher in RM11A+Dox/ErbB2 cells
(Figure 4b) compared to RM11A+Dox cells (Figure 4a)
at 4 days post cell injection. Upon quantitative analysis,
a statistically significant 1.3-fold increase in Ki67 positiv-
ity was observed in the RM11A+Dox/ErbB2 tumor cells
compared to RM11A+Dox tumor cells (Figure 4e).
However, there were no significant difference in Ki67
staining between RM11A+Dox tumor cells (Figure 4c)
and RM11A+Dox/ErbB2 tumor cells 14 d post injection
(Figure 4d), suggesting that ErbB2 increases tumor
growth rate during the first few days of tumor develop-
ment but not once tumors have been established. In
addition, no correlation was observed between tumor
size and percent Ki67 staining (data not shown), indicat-
ing that proliferation was not dependent on tumor size.
Two methods were used to further quantify tumor
growth rate after the formation of palpable nodules;
SGR and tumor doubling time. As seen in Table 2,
there was no significant difference in average SGR
values in tumors induced by RM11A+Dox cells com-
pared to RM11A+Dox/ErbB2 cells. Similarly, doubling
time was not accelerated by ErbB2 addition. These
results strongly indicate that ErbB2 overexpression does
not enhance tumor growth rate once the tumors
become large enough to be palpated.
ErbB2 overexpression impairs regression and enhances
metastasis following IGF-IR downregulation
Previously it has been observed that most tumors
formed after injection of RM11A+Dox cells into the
mammary gland regress following IGF-IR downregula-
tion, with most of these tumors recurring independent
of IGF-IR transgene expression [49]. To examine the
effect of ErbB2 overexpression on tumor regression in
our model, RM11A+Dox and RM11A+Dox/ErbB2 cells
were injected into the mammary gland of wild type
mice. Once tumors reached 7-11 mm in length
Table 1 Summary of tumor development in FVB mice
injected with RM11A stable transfectants
RM11A+Dox RM11A+Dox/ErbB2
Number of mice injected 38 31
Number of palpable tumors 29 42
Number of tumors per mouse 0.76 1.35
Average tumor latency (d) 47.9 22.1
a
a Significantly lower than RM11A-+Dox (p < 0.001)
Figure 2 RM11A+Dox/ErbB2 cells maintain ErbB2 and IGF-IR overexpression in vivo. Western blot analysis of IGF-IR and ErbB2 in RM11A
+Dox cells expressing high levels of IGF-IR and RM11A+Dox/ErbB2 cells expressing high levels of both IGF-IR and ErbB2 following in vivo tumor
growth. b-actin served as a loading control. Tissue was collected when tumors reached 17 mm in length.
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Page 6 of 16Figure 3 ErbB2 overexpression enhanced tumor size with IGF-IR induction after 14 days. H&E stained mammary sections 14 days after
injection of RM11A+Dox injected mammary glands (a, b, c) and RM11A+Dox/ErbB2 injected mammary glands (d, e, f) are shown. Scale bars: 1
mm for (a-f). Quantification of tumor area is presented in (h). Asterisk = p < 0.05.
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3 in volume) IGF-IR trans-
gene expression was suppressed by switching the ani-
mals from a doxycycline diet to a normal diet (animals
remained on a normal diet for the remainder of the
study). Tumor length prior to IGF-IR downregulation
did not significantly vary between the RM11A+Dox and
RM11A+Dox/ErbB2 groups. As shown in Table 3, the
presence of ErbB2 impaired tumor regression following
IGF-IR transgene downregulation (doxycycline withdra-
wal). RM11A cells with elevated ErbB2 levels failed to
Figure 4 ErbB2 overexpression enhanced proliferation in vivo shortly after injection. Immunohistochemistry for Ki67 in mammary glands
injected with RM11A+Dox (a, c) and RM11A+Dox/ErbB2 (b, d) cells 4 (a, b) or 14 (c, d) days after cell injection into the mammary fat pad.
Quantification of Ki67 staining revealed a significant increase in proliferation at day 4 but not day 14 in the RM11A+Dox/ErbB2 tumors compared
to RM11A+Dox tumors (e). Scale bars: 100 μm.
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partially regress. In contrast, 27% of RM11A+Dox
tumors completely regressed following IGF-IR transgene
downregulation and only 9% of the tumors failed to at
least partially regress (Table 3). Using a chi-square test,
the difference in tumor regression characteristics was
determined to be statistically significant (p < 0.05).
To determine whether ErbB2 overexpression altered
the metastatic capacity of RM11A cells, lung tissue from
mice harboring primary tumors (15-17 mm in length)
or tumors that recurred following IGF-IR transgene
downregulation (15-17 mm in length) was analyzed. As
shown in Table 4, the incidence of microscopic lung
metastasis from primary mammary tumors derived from
RM11A+Dox cells was relatively infrequent with only 3
of 21 mice developing lung metastases. Overexpression
of ErbB2 in the presence of high IGF-IR expression did
not enhance metastasis to the lung as only 2 of 19 mice
with primary tumors derived from RM11A+Dox/ErbB2
cells developed lung metastases. Representative images
of metastasis resulting from the injection of RM11A
+Dox and RM11A+Dox/ErbB2 are shown in Figure 5a
and 5b respectively.
Lung metastasis was also examined in mice harboring
RM11A+Dox and RM11A+Dox/ErbB2 tumors that grew
following IGF-IR transgene downregulation. Six of 13
tumors expressing high levels of ErbB2 metastasized to
the lung while none of the tumors with basal ErbB2
expression metastasized to the lung (Figure 5c, d). In
addition, these lung metastases were macroscopic and
liver metastases were also observed (liver metastases
have never been observed previously in RM11A cells).
Confirmation of IGF-IR downregulation in doxycycline-
independent recurrent tumors and metastases as well as
upregulation of ErbB2 in RM11A+Dox/ErbB2 doxycy-
cline-independent tumors and metastases is shown in
Figure 5e, f. Therefore, tumors initially expressing high
levels of both IGF-IR and ErbB2 (RM11A+Dox/ErbB2)
are metastatic and this metastatic potential appears to
increase following IGF-IR downregulation.
ErbB2 is overexpressed in metastatic lesions from MTB-
IGFIR transgenic mice
Metastasis to the lung has been observed in approxi-
mately 40% of MTB-IGFIR transgenic mice harboring
tumors 15-17 mm in length and these metastases range
in size from microscopic lesions of approximately 50-
100 μm in length to macroscopic tumors approximately
6-8 mm in length (unpublished observations). To deter-
mine whether ErbB2 is involved in metastasis of mam-
mary tumors produced by MTB-IGFIR transgenic mice,
immunohistochemistry for ErbB2 was performed on the
aforementioned lung tissue. While a relatively high level
of variability was observed in both primary tumors and
microscopic lung metastases, there was a tendency for
lung lesions to stain more intensely for ErbB2 than pri-
mary tumors (Figure 6a-c and 6d-f respectively).
Through quantification of staining, this was verified as
there was an approximate 2-fold increase in positive
staining in metastases (Figure 6g). Some of the larger
l u n gl e s i o n sw e r eo b s e r v e dt oh a v ee s p e c i a l l yi n t e n s e
ErbB2 staining (examples shown include Figure 6a, c);
this translated to a 30-fold increase in strong positive
staining in metastatic lesions compared to primary
mammary tumors (Figure 6g). In metastatic lesions
from MTB-IGFIR mice, the levels of ErbB2 and the acti-
vation status of ErbB2 were confirmed using western
blots. Isolated lung metastases displayed very high levels
of ErbB2 and phosphorylated ErbB2 (Figure 7a, b).
Interestingly, primary mammary tumors from mice with
Table 3 Summary of tumor regression after IGF-IR
downreguation (% reduction in volume)
Number of
tumors with full
regression
(100%)
Number of tumors
with partial
regression
(10-99.9%)
Number of tumors
with no/minimal
regression (0-10%)
RM11A
+Dox
3/11 (27.2%) 7/11 (63.6%) 1/11 (9.1%)
RM11A
+Dox/
ErbB2
0/14 (0.0%) 7/14 (50.0%) 7/14 (50.0%)
Significantly different between the two conditions tested (p < 0.05)
Table 4 Summary of metastasis in FVB mice injected with
RM11A-ErbB2 stable transfectants
RM11A
+Dox
RM11A
+Dox/
ErbB2
RM11A+Dox
after IGF-IR
suppression
RM11A+Dox/-
ErbB2 after IGF-
IR suppression
Number of mice 21 19 12 13
Number with
microscopic lung
metastasis
32 0 6
Percent with
metastasis
14.3 10.5 0.0 46.2
a
Number of mice
with macroscopic
lung metastasis
00 0 3
Number of mice
with macroscopic
liver metastasis
00 0 1
a Significantly different than RM11A+Dox after IGF-IR suppression (p < 0.05)
Table 2 Summary of tumor growth rate in FVB mice
injected with RM11A-ErbB2 stable clones
RM11A+Dox RM11A+Dox/ErbB2
Specific growth rate (%/d) 17.9 ± 2.0 15.8 ± 1.4
Doubling time (d) 4.4 ±0.2 5.4 ± 0.4
a
a Significantly higher than RM11A+Dox (p < 0.05)
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Page 9 of 16Figure 5 Metastasis was observed after injection of RM11A variants. H&E stained sections of lung tissue with metastasis following intra-
mammary injection and subsequent mammary tumor development of RM11A+Dox (b) or RM11A+Dox/ErbB2 injected mice (a) are shown
(arrows). Typically these lesions were relatively small. Metastasis was also observed to occur following IGF-IR downregulation in RM11A+Dox/
ErbB2-injected animals and these lesions were usually larger than aforementioned lesions (c, d); (LM = lung metastasis; NL = normal lung). Scale
bars: 100 μm. Western blotting was performed on protein lysates from RM11A+Dox and RM11A+Dox/ErbB2 doxycycline-independent recurrent
tumors and metastases to confirm IGF-IR and ErbB2 levels (e). Relative quantification is shown in (f).
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Page 10 of 16Figure 6 Metastatic lesions from MTB-IGFIR transgenic mice display elevated ErbB2 expression. Representative ErbB2 staining in lung
sections (a, b, c) and primary tumors (d, e, f); LM denotes the metastatic lung lesion, while NL refers to surrounding normal lung tissue.
Quantitative analysis revealed that an approximate 2-fold higher level of positivity (p = 0.15) and a 30-fold increase in strong positive labeled
cells (p = 0.16) in metastases compared to primary tumors (g).
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Page 11 of 16lung metastases also displayed high levels of ErbB2 and
phosphorylated ErbB2 compared to primary mammary
tumors from mice with no evidence of lung metastases
(Figure 7a, b). Taken together these data suggest that
metastatic tumor cells express elevated levels of ErbB2.
Discussion
While the contribution of the IGF-IR to ErbB2 signaling
and resistance to ErbB2-directed therapies in breast can-
cer has been studied in several systems, the reciprocal
interaction remains almost completely unknown. To
study the potential role of ErbB2 during IGF-IR-
mediated mammary tumorigenesis we utilized our
model of inducible IGF-IR overexpression. The impor-
tance of the IGF-axis in proliferation and transformation
of a vast number of cells including human mammary
epithelial cells is well documented. Our laboratory has
shown that IGF-IR overexpression alone is capable of
mediating an extremely rapid transformation of mouse
mammary epithelial cells [21]. Most of these tumors
remained dependent on transgene expression as IGF-IR
transgene downregulation resulted in tumor regression
in a majority of these tumors. A small subset of tumors
was capable of resuming growth in the absence of IGF-
IR transgene expression [49]. Similarly, RM11A cells
grown in the mammary fat pad of syngeneic wild type
mice developed tumors more rapidly when IGF-IR
transgene expression was induced and IGF-IR transgene
downregulation resulted in the regression of most of the
tumors. Unlike the transgenic mammary tumors, most
of the RM11A induced tumors eventually resumed
growth following IGF-IR transgene downregulation [43].
Figure 7 ErbB2 was upregulated in metastatic tumors. Western blotting for ErbB2 and pErbB2 in primary mammary tumors from MTB-IGFIR
mice that did not metastasize, primary mammary tumors that did metastasize and isolated lung metastases (a). Densitometry revealed that
ErbB2 and pErbB2 levels were approximately 2-fold higher in tumors from mice with metastases (p = 0.10 for both ErbB2 and pErbB2) and
approximately 3-fold higher in metastatic lesions (p = 0.09 for ErbB2 and p = 0.10 for pErbB2) compared to primary mammary tumors that did
not metastasize (b).
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Page 12 of 16Therefore, while IGF-IR-induction remains very impor-
tant for mammary tumorigenesis in our model, clearly
alterations in the expression of other genes/proteins can
be acquired during tumorigenesis, which allow tumors
to grow independent of the IGF-IR transgene. Given the
prominent role of ErbB2 in breast cancer and the pre-
viously discussed interactions with the IGF-IR, this
oncogene was an attractive candidate.
Selection of stable transfectants yielded RM11A cells
with approximately 3-fold higher expression of ErbB2
(RM11A+Dox/ErbB2) than control RM11A cells
(RM11A+Dox). Phosphorylated ErbB2 was also elevated
approximately 3-fold in the ErbB2 overexpressing cells
thus indicating the receptor was active. This overexpres-
sion was monitored and consistently maintained
throughout the duration of the study (representative
western blot is shown in Figure 1). It is well understood
that breast cancer tissue and cell lines can contain
upwards of 50-100-fold higher levels of ErbB2 protein
compared to normal tissue and these levels are typically
associated with gene amplification and poor prognosis
[50,51]. While a modest overexpression was achieved in
our cell line, two points should be taken into considera-
tion; first, RM11A cells intrinsically contain high levels
of ErbB2. In addition, recent studies have shown a cor-
relation between low-level ErbB2 expression (compar-
able to normal mammary tissue) and an overall
unfavorable disease outcome [52,53].
To control for phenotypes caused by integration of the
plasmid, we utilized two separate clones for both control
and ErbB2 overexpressing stable integrants. Interest-
ingly, the ErbB2 antibody detected two additional bands
only in clones with pEN1-ErbB2 integration (and not
with the control plasmid). These bands were determined
to be approximately 95 and 70 kDa. A 95 kDa truncated
N-terminal product of Her2, known as p95Her-2, has
been previously described [54]. This degradation pro-
duct arises from proteolytic cleavage and subsequent
release of the extracellular domain [55,56]. While the
function of this protein is largely unknown, it has been
shown to contribute to herceptin resistance [57]. In
addition, it was observed that higher levels of this pro-
duct correlated with shorter disease free survival and
increased lymph node metastasis [58-60]. Thus, the pre-
sence of this ErbB2 degradation product appears to con-
tribute to tumorigenesis. In our cell line, the presence of
s u c hap r o d u c tw o u l di n d i c a t et h a ts t a b l ei n t e g r a t i o n
of this expression vector has yielded a threshold level of
ErbB2 expression required for significant production of
this cleavage product.
Downstream signaling pathways were studied to deter-
mine those potentially augmented by ErbB2 overexpres-
sion. The levels of phosphorylated Akt and Erk1/2 were
similar in RM11A+Dox cells and RM11A+Dox/ErbB2
cells suggesting that upregulation of ErbB2 was incap-
able of further activating PI-3K or MAPK pathways.
Given the magnitude of IGF-IR overexpression and the
fact that both of these pathways are known to be acti-
vated by this receptor this observation is not surprising;
it is anticipated that the high level of IGF-IR expression
has already maximized signaling though the PI-3K and
MAPK pathways [43].
In vivo, it was observed that ErbB2 conferred a more
rapid tumor onset and tumor incidence was also ele-
vated as indicated by the number of mammary glands
injected that actually developed tumors. To verify that
ErbB2 shortened tumor latency, mammary glands were
collected 14 d post-injection. Average tumor size at this
time point was 4-fold greater in the RM11A+Dox/ErbB2
cells compared to RM11A+Dox cells. We then explored
possible mechanisms through which ErbB2 augmented
tumor growth. First we looked at survival and prolifera-
tion in vitro. Only a small, insignificant increase in sur-
vival was observed in RM11A+Dox/ErbB2 cells were
compared to RM11+Dox cells and thus it was concluded
that ErbB2 overexpression had a negligible effect on
RM11A cell survival in vitro. Despite a minimal effect in
vitro, overexpression of ErbB2 had a marked effect on
tumorigenesis in vivo. Using Ki67 staining to examine
proliferation our data suggested that proliferation is only
significantly affected by ErbB2 overexpression shortly
after tumor cells colonize the mammary tissue (4 d post
injection but not 14 d post injection). The lack of differ-
ence in proliferation in established tumors was corrobo-
rated by evaluating tumor growth rates using two
independent methods. For the first method log(tumor
volume) was plotted against time and from the resulting
slope of the line tumor doubling time was calculated.
The second technique, specific growth rate has been
mathematically determined to be an accurate means of
quantifying tumor growth rate and is less susceptible to
negligible or negative changes in volume from one mea-
surement to the next [61]. In this experiment, tumor
volumes were sometimes observed to decrease before
ultimately increasing again and thus this model of
growth rate was deemed appropriate. Both methods
yielded similar results and showed that ErbB2 overex-
pression did not enhance tumor growth rate. Therefore,
it was concluded that in the presence of IGF-IR overex-
pression, ErbB2 facilitates proliferation during initial
tumor establishment but has no effect on tumor
growth/proliferation after this point.
Tumor regression following IGF-IR transgene downre-
gulation was studied to model the effects of ErbB2 over-
expression during the use IGF-IR-directed therapeutics.
Here it was observed that ErbB2 overexpression
impaired tumor regression following IGF-IR downregu-
lation thus suggesting that ErbB2 could potentially
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Page 13 of 16facilitate resistance to IGF-IR-directed therapies. These
results are of obvious clinical importance as ErbB2 sta-
tus may become an important predictor of response to
IGF-IR-directed therapies. In addition, subsequent muta-
tions enhancing ErbB2 expression may render tumors
unresponsive to these therapies. It is becoming clear
that IGF-IR can mediate resistance to ErbB2-targeting
treatments [33]; therefore, it stands to reason that the
reciprocal interaction may also be important.
Metastasis was also studied for multiple reasons; first,
ErbB2 expression is well known to correlate with distant
metastasis in human clinical breast cancer [62]. Also,
overexpression of this oncogene has been shown to
increase the metastatic potential of human breast cancer
cell lines [63]. Lastly, in transgenic models of ErbB2
overexpression, metastasis to the lung is a common
occurrence [2]. Contrary to our expectations, ErbB2
overexpression did not facilitate an increase in lung
metastasis. This could be due to the rapid establish-
ment, onset and subsequent growth rate in primary
tumors formed with both IGF-IR and ErbB2 overexpres-
sion; for this condition time elapsed between tumor
onsets and euthanizing the animals was only 31 days on
average and sometimes as short as 15 days, while palp-
able tumor onset occurred as early as 7 days post
injection.
ErbB2 overexpression did however facilitate metastasis
following IGF-IR downregulation. It is possible that
through the delayed process of partial regression and
subsequent resumption of growth, metastasic lesions
have time to grow to a size where they are detectable
histologically. Furthermore, upregulation of ErbB2 was
observed in metastatic primary tumors as well as many
metastatic lesions from MTB-IGFIR mice compared to
non-metastatic primary tumors. Based on the fact that
metastasis is only observed in 40% of all MTB-IGFIR
animals, it is apparent that other alterations must occur
to confer metastatic competency. Our results suggest
that upregulation of ErbB2 is one such mechanism
through which tumor cells gain this capacity. These
observations suggest that ErbB2 can compensate for the
loss of IGF-IR signaling during mammary tumorigenesis
and further supports a potential advantage in combining
ErbB2 and IGF-IR-directed therapies.
In conclusion, this study describes experiments pro-
viding information regarding the interaction between
two potent oncogenes in mammary tumorigenesis. It
has been previously postulated that targeting multiple
signaling pathways such as IGF-IR and ErbB2 may be
beneficial to the treatment of breast cancer [35]. Based
on our results, it is suggested that ErbB2 can augment
IGF-IR-dependent mammary tumorigenesis by enhan-
cing initial colonization and proliferation as well as fol-
lowing IGF-IR suppression.
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